Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Aug 2;4(8):e2121697.
doi: 10.1001/jamanetworkopen.2021.21697.

Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort

Affiliations
Comparative Study

Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort

Joshua T Fox-Fuller et al. JAMA Netw Open. .

Abstract

Importance: We previously reported that children with the autosomal dominant Alzheimer disease (ADAD) presenilin 1 (PSEN1) E280A variant had early life plasma biomarker findings consistent with amyloid β overproduction. However, the cognitive functioning of children with this variant has not been characterized vs those without the variant.

Objective: To test whether cognitive functioning of children with and without the PSEN1 E280A variant in the same ADAD cohort differed by genetic status (ie, PSEN1 variant) and sex.

Design, setting, and participants: This cohort study was conducted among 1354 children (including 265 children with the variant) aged 6 to 16 years recruited from the Alzheimer Prevention Initiative Colombia Registry. Participants from the city of Medellín and surrounding suburban areas traveled to the University of Antioquia to undergo all procedures. Participants were administered a Spanish version of the Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV) to measure general cognitive functioning. Data were analyzed from July through November 2020.

Main outcomes and measures: Univariate general linear models were used to characterize differences on WISC-IV cognitive performance by genetic status, sex, and the interaction of genetic status with sex. Urbanity, socioeconomic status, and education were entered as covariates.

Results: Among 1354 children with ADAD (695 [51.3%] girls; mean [SD] age, 11.64 [2.64] years), there were 265 children with the variant (19.6%) and 1089 children without the variant (80.4%). Children with and without the variant did not differ by demographic variables or performance on WISC-IV indices. Irrespective of genetic status, boys had statistically significantly decreased mean scores on indices for working memory (90.27 [95% CI, 89.21-91.34] vs 92.99 [95% CI, 91.98-93.99]; mean difference = -2.72; P < .001), perceptual reasoning (91.56 [95% CI, 90.47-92.65] vs. 93.27 [95% CI, 91.23-94.30]; mean difference = -1.71; P = .03), and verbal comprehension (88.69 [95% CI, 87.54-89.84] vs. 90.81 [95% CI, 89.73-91.90]; mean difference = -2.12; P = .009) compared with girls. In the interaction between sex and genetic status, boys with the variant had worse mean working memory index performance (88.78 [95% CI, 86.86-90.70]) than girls with the variant (93.75 [95% CI, 91.95-95.55]; mean difference = -4.97; P = .001), as well as boys (91.77 [95% CI, 90.85-92.70]; mean difference = -2.99; P = .04) and girls (92.22 [95% CI, 91.32-93.13]; mean difference = -3.44; P = .009) without the variant.

Conclusions and relevance: This study found that boys with the PSEN1 variant had decreased working memory abilities compared with girls with the variant and boys and girls without the variant, suggesting a sex-specific genetic risk in early life cognitive performance among individuals with the PSEN1 variant. This increased risk of future cognitive difficulties among boys with the variant may have important downstream implications for learning and academic achievement and could be associated with sex differences seen in adulthood on episodic memory measures.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Quiroz reported receiving grants from the National Institutes of Health Office of the Director, and Alzheimer’s Association outside the submitted work. Dr Lopera reported receiving support from an anonymous foundation; grants from the Colombian Administrative Department of Science, Technology and Innovation; National Institutes of Health; Banner Alzheimer’s Foundation; and Alzheimer’s Prevention Initiative (API) Colombia during the conduct of the study; and personal fees from the National Institutes of Health and API Colombia outside the submitted work. Drs Reiman, Lopera, and Tariot reported serving as principal investigators of the API Autosomal Dominant Alzheimer’s Disease Trial, which is supported by the National Institute on Aging (NIA), anonymous philanthropy, Genentech, and Roche. Dr. Reiman reported receiving support from the Banner Alzheimer’s Foundation and Nomis Foundation; research funding from Avid; and consulting fees from Eli Lilly. Dr Tariot reported receiving consulting fees from AbbVie, AC Immune, Boehringer Ingelheim, Chase Pharmaceuticals, CME, Genentech, MedAvante ProPhase, Otsuka, Eli Lilly, AstraZeneca, Avanir, Merck, Pfizer, and Roche; receiving research support from AstraZeneca, Avanir, Eli Lilly, Merck, Novartis, Roche, Functional Neuromodulation, GE Healthcare, Genentech, Pfizer, Avid Radiopharmaceuticals, and the Arizona Department of Health Services; owning stock options in Adamas Pharmaceuticals; and contributing to a patent for biomarkers of Alzheimer disease owned by the University of Rochester during the conduct of the study. Dr Chen reported receiving grants from the NIA and Arizona State University (ASU) during the conduct of the study; receiving personal fees from Green Valley, Beijing Normal University, and 6th People’s Hospital; and serving as faculty for the University of Arizona and ASU outside the submitted work. Dr Langbaum reported receiving grants from the NIA, Genentech, and Roche during the conduct of the study and personal fees from Alector and Biogen and grants from Novartis outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Performances on WISC-IV Indices by Sex and Genetic Status
Shown are violin plots of standard score performances of children with the variant (in orange) and without the variant (in blue) on WISC-IV by biological sex. Thick middle lines of internal box plots indicate median values; tops and bottoms of boxes, interquartile range; whiskers, variability in scores outside of the interquartile values; black circles, statistical outliers; width of violin plot at any point, probability of values from the represented sample being at that value, with wider sections representing higher frequencies of values at that point in the distribution; WISC-IV, Wechsler Intelligence Scale for Children, Fourth Edition. Clinically, standard scores have a mean (SD) of 100 (15).

References

    1. Fuller JT, Cronin-Golomb A, Gatchel JR, et al. . Biological and cognitive markers of presenilin1 E280A autosomal dominant Alzheimer’s disease: a comprehensive review of the Colombian kindred. J Prev Alzheimers Dis. 2019;6(2):112-120. - PMC - PubMed
    1. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, et al. . Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet Neurol. 2011;10(3):213-220. doi:10.1016/S1474-4422(10)70323-9 - DOI - PubMed
    1. Quiroz YT, Schultz AP, Chen K, et al. . Brain imaging and blood biomarker abnormalities in children with autosomal dominant Alzheimer disease: a cross-sectional study. JAMA Neurol. 2015;72(8):912-919. doi:10.1001/jamaneurol.2015.1099 - DOI - PMC - PubMed
    1. Vila-Castelar C, Guzmán-Vélez E, Pardilla-Delgado E, et al. . Examining sex differences in markers of cognition and neurodegeneration in autosomal dominant Alzheimer’s disease: preliminary findings from the Colombian Alzheimer’s Prevention Initiative Biomarker Study. J Alzheimers Dis. 2020;77(4):1743-1753. doi:10.3233/JAD-200723 - DOI - PMC - PubMed
    1. Laws KR, Irvine K, Gale TM. Sex differences in Alzheimer’s disease. Curr Opin Psychiatry. 2018;31(2):133-139. doi:10.1097/YCO.0000000000000401 - DOI - PubMed

Publication types